Panagene Inc (046210) - Total Liabilities

Latest as of September 2025: ₩24.65 Billion KRW ≈ $16.70 Million USD

Based on the latest financial reports, Panagene Inc (046210) has total liabilities worth ₩24.65 Billion KRW (≈ $16.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Panagene Inc - Total Liabilities Trend (2005–2024)

This chart illustrates how Panagene Inc's total liabilities have evolved over time, based on quarterly financial data. See Panagene Inc (046210) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Panagene Inc Competitors by Total Liabilities

The table below lists competitors of Panagene Inc ranked by their total liabilities.

Company Country Total Liabilities
Momentus Inc
NASDAQ:MNTS
USA $23.18 Million
Radana Bhaskara Finance Tbk
JK:HDFA
Indonesia Rp3.07 Trillion
Cowealth Medical Holding Co Ltd
TWO:4745
Taiwan NT$1.99 Billion
Duxton Farms Ltd
AU:DBF
Australia AU$123.41 Million
Alternative Investment Trust
AU:AIQ
Australia AU$261.00K
Acula Technology
TWO:3434
Taiwan NT$199.05 Million
ELUON Corporation
KQ:065440
Korea ₩26.80 Billion
Jembo Cable Company Tbk
JK:JECC
Indonesia Rp1.66 Trillion

Liability Composition Analysis (2005–2024)

This chart breaks down Panagene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Panagene Inc (046210) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Panagene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Panagene Inc (2005–2024)

The table below shows the annual total liabilities of Panagene Inc from 2005 to 2024.

Year Total Liabilities Change
2024-12-31 ₩33.57 Billion
≈ $22.75 Million
+22.77%
2023-12-31 ₩27.34 Billion
≈ $18.53 Million
+816.19%
2022-12-31 ₩2.98 Billion
≈ $2.02 Million
+44.46%
2021-12-31 ₩2.07 Billion
≈ $1.40 Million
-4.43%
2020-12-31 ₩2.16 Billion
≈ $1.46 Million
+36.64%
2019-12-31 ₩1.58 Billion
≈ $1.07 Million
-79.65%
2018-12-31 ₩7.77 Billion
≈ $5.27 Million
-3.51%
2017-12-31 ₩8.06 Billion
≈ $5.46 Million
-32.42%
2016-12-31 ₩11.92 Billion
≈ $8.08 Million
-28.76%
2015-12-31 ₩16.73 Billion
≈ $11.34 Million
+0.92%
2012-12-31 ₩16.58 Billion
≈ $11.24 Million
-37.39%
2011-12-31 ₩26.48 Billion
≈ $17.95 Million
+22.33%
2010-12-31 ₩21.65 Billion
≈ $14.67 Million
+44.59%
2009-12-31 ₩14.97 Billion
≈ $10.15 Million
-38.62%
2008-12-31 ₩24.39 Billion
≈ $16.53 Million
+47.48%
2007-12-31 ₩16.54 Billion
≈ $11.21 Million
-40.36%
2006-12-31 ₩27.73 Billion
≈ $18.79 Million
-43.96%
2005-12-31 ₩49.49 Billion
≈ $33.54 Million
--

About Panagene Inc

KQ:046210 Korea Biotechnology & Medical Research
Market Cap
$33.71 Million
₩49.75 Billion KRW
Market Cap Rank
#23427 Global
#1567 in Korea
Share Price
₩1548.00
Change (1 day)
-2.64%
52-Week Range
₩1373.00 - ₩2650.00
All Time High
₩12000.00
About

Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more